Certara’s Dr. Fran Brown, Senior Vice President of Drug Development Science, is quoted in this WIRED article about the FDA’s recent rejection of Lykos Therapeutics’ proposed MDMA treatment for post-traumatic stress disorder. Read the article for her insights into the challenges of designing clinical trials to assess the therapeutic potential of psychedelics.
The Uncertain Path Forward for Psychedelic Medicine
8월 26, 2024